Section Sub-head
Header
Sub-head
Header
Sub-head
-
Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide
Hypertension, or high blood pressure, affects nearly half of all Americans and more than one billion people worldwide. Hypertension is known as the “silent killer” because many people do not know they have it and, over time, it can lead to serious health issues. Hypertension is the number one contributor to the burden of human…
-
Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), announce the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension in the United Arab Emirates (UAE). Three cases were performed at Al Qassimi Hospital in Sharjah by Dr. Arif Al Nooryani and…
-
Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation therapy in the United States. The first commercial procedures took place at NewYork-Presbyterian/Columbia University Irving…
-
Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
-
Recor Medical Announces Positive Results from Six-Month Pooled Analysis of Data from the RADIANCE Global Clinical Trial Program at TCT 2023
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced positive results from a combined analysis of six-month follow-up data from the three RADIANCE global clinical studies evaluating the Paradise™ Ultrasound Renal Denervation (uRDN) system as a treatment for hypertension. Analysis demonstrated maintained blood pressure (BP) reduction…
-
Recor Medical to Present Latest Clinical Data on Paradise® Ultrasound Renal Denervation at TCT Annual Meeting
Recor Medical, Inc. (“Recor”), a subsidiary of Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), will present data from several clinical studies of the Paradise® Ultrasound Renal Denervation (uRDN) system in the treatment of hypertension at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco.